GLP-1 Hair Loss: What to Do When Shedding Won't Stop

Do GLP-1s cause hair loss?

Hair loss is reported more often with GLP-1 medications than with placebo in clinical trials, though most participants did not report it. Trial tables list events that occurred during a study, so they cannot show on their own whether the medicine, the weight loss, or something else caused a particular case.

In the three placebo-controlled trials of adults with obesity or overweight pooled in the Wegovy prescribing information, hair loss was reported by 3% of the 2,116 people taking Wegovy 2.4 mg by weekly injection and 1% of the 1,261 people taking placebo, over up to 68 weeks. The label lists higher-dose results separately, so those figures apply only to the 2.4 mg dose. For hair loss on tirzepatide (Zepbound), the pooled placebo-controlled weight-reduction trials in adults with obesity or overweight described in the Zepbound prescribing information, which ran up to 72 weeks, reported hair loss in 5% of people at 5 mg, 4% at 10 mg, and 5% at 15 mg weekly, versus 1% on placebo.

No patient taking Zepbound stopped the study medicine because of hair loss, and one patient taking placebo did. Both labels describe hair loss as associated with weight reduction and note that women reported it more often than men, without explaining why. These are separate trials with different doses, populations, and lengths, so the figures should not be used to rank one medicine above another.

A 2026 study in The BMJ (Tang et al.) looked at GLP-1 and hair loss in Penn Medicine health records of adults with type 2 diabetes: 12,004 who started a GLP-1 medicine and 15,221 who started an SGLT-2 inhibitor, a different class of diabetes medicine. After the researchers adjusted for differences between the groups, about 7 of every 1,000 people followed for a year had hair loss recorded in the GLP-1 group, compared with about 5 in the SGLT-2 group. The difference was concentrated in non-scarring alopecia, meaning hair loss that does not permanently destroy follicles, and the link weakened in one of the researchers' checks for hidden bias. Both rates were low. Because this was an observational study in people with type 2 diabetes, it shows an association, cannot prove the medicines caused the difference, and may not apply to people taking them for weight loss.

What GLP-1 related shedding can look like

Hair grows in cycles. At any moment most scalp hairs are in a growth phase, called anagen, and a smaller share are in a resting phase, called telogen, before they shed. A physical stressor such as rapid weight loss, illness, or surgery can move more follicles into the resting phase at once. The extra shedding that follows is called telogen effluvium, and it typically becomes noticeable a few months after the trigger. That timing is general guidance for telogen effluvium, not a schedule specific to GLP-1 medicines.

Telogen effluvium tends to look diffuse, meaning thinner across the whole scalp with more hair on the brush or in the shower, rather than a bald patch. Researchers who reviewed the published reports (Gupta et al., Science Progress, 2026) described most reported cases as resembling telogen effluvium. Reviews of reports describe what people have experienced and cannot show what caused hair loss in any one person.

Pattern hair loss, known as androgenetic alopecia, can look similar at first, and the two can occur together. A 2025 database study in JEADV Clinical Practice (Ching et al.) found an association between semaglutide and androgenetic alopecia. An association like that cannot show whether the medicine contributed to the thinning or whether the thinning was already underway, and telling the two apart takes an examination.

Hair loss that is patchy or circular, comes with scalp pain, or shows signs of scarring looks different from diffuse shedding and deserves a dermatologist's attention.

Why weight loss may matter

GLP-1 medicines slow stomach emptying and reduce appetite, which can lead to weight loss that is large and fast. Rapid weight loss is a recognized trigger for telogen effluvium, so it is a reasonable suspect in GLP-1 related shedding, and eating less can also lower protein and micronutrient intake. Shedding is also reported after bariatric surgery, another route to fast weight loss (Zhang et al., Obesity Surgery, 2021). Reports like these fit the idea that weight loss and reduced nutrition contribute, but they cannot separate those factors from the effect of any specific medicine, and they do not show that one route to weight loss causes more or less shedding than another. Whether GLP-1 medicines affect hair beyond the weight loss itself has not been established.

What to expect as shedding settles

In telogen effluvium generally, shedding often starts to ease within several months once the trigger settles. Visible fullness usually returns more slowly, since new hairs have to grow in and lengthen. These are approximate expectations from general guidance, not a validated GLP-1 recovery schedule, and some people's shedding lasts longer. Shedding easing and fullness returning are separate milestones, so one can happen well before the other.

There is no set number of months you need to wait before asking for an assessment. If the shedding worries you, a clinician can look at it now.

Nutrition guidance exists, but no GLP-1 hair loss supplement is shown to stop shedding

A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society outlines nutritional priorities for people taking GLP-1 medicines, among them preventing micronutrient deficiencies and keeping protein intake adequate alongside resistance training (Obesity, 2025). A separate expert consensus built through a Delphi process offers protein recommendations for people losing weight (Obesity Pillars, 2026). The right protein amount depends on the person, so a prescriber or dietitian is a good source for a personal target. Both documents address nutrition during GLP-1 therapy in general, and neither shows that a protein target or a supplement prevents or resolves hair shedding.

In a 2021 review of people who had bariatric surgery, lower levels of some nutrients, including zinc, folate, and ferritin, were associated with hair loss (Zhang et al., 2021). That is an association in a different group of people, and it does not show that taking those nutrients would stop GLP-1 related shedding.

Blood tests and biotin

Ferritin is a protein that stores iron, and a ferritin blood test helps estimate how much iron the body has stored. Whether to test ferritin, zinc, folate, thyroid function, or vitamin D depends on your history and diet, and a clinician can decide which tests fit.

High-dose biotin can interfere with some laboratory tests, including troponin tests used to help diagnose heart attacks, where it has caused falsely low results. Anyone taking biotin can tell the person ordering or running their lab tests.

GLP-1 hair loss: when to get help

A clinician's assessment is reasonable at any point, and it is especially useful if you notice any of these:

• Patchy or circular hair loss

• Scalp pain, burning, or visible scarring

• Shedding that is heavy, keeps going, or worries you

• Pregnancy or nursing

• A question about adjusting a prescription medication

If pattern hair loss turns out to be part of the picture, a dermatologist can discuss options, including topical minoxidil, which is FDA-approved for androgenetic alopecia. It has not been established as a remedy for GLP-1 related shedding, and the sources reviewed here did not identify any remedy for tirzepatide-related hair loss. Results vary, and minoxidil can irritate the scalp.

A short list of questions worth bringing to the appointment:

• Would checking ferritin, zinc, folate, thyroid function, or vitamin D make sense given how I am eating right now?

• Does my rate of weight loss look faster than expected for my dose?

• Would it make sense to raise my dose more slowly, given my goals?

• Does my hair loss look like a diffuse shed, or does it match a pattern I have seen in family members?

Mention any personal or family history of thinning, ideally before starting a GLP-1 medicine. If you are wondering whether the medication is worth it because of your hair, bring that question to your prescriber too, especially if the medication is helping your weight or blood sugar.

Frequently asked questions

Will my hair grow back after shedding on a GLP-1 medicine?

Hair can regrow after telogen effluvium in general, but no recovery schedule has been established for GLP-1 related shedding, and the outcome varies from person to person. Shedding usually eases before visible fullness returns. A clinician can assess your shedding at any point, and there is no minimum waiting period.

How can I tell telogen effluvium from pattern hair loss?

Diffuse shedding across the scalp looks different from thinning at the part or hairline, and the two can occur together, so an examination is the way to tell them apart. A dermatologist can look at your scalp and decide whether tests are needed. Photos of how your hair looked before the shedding, and any family history of thinning, help that conversation.

Is one GLP-1 medicine more likely to cause hair loss than another?

Hair loss with tirzepatide (Zepbound) and with semaglutide (Wegovy) is listed as an adverse reaction on both labels, and the studies differ in dose, population, and length. The available data do not support ranking one medicine above another, and no single figure is a fixed risk for any one person. Retatrutide and hair loss are not covered by the sources reviewed here, and Eli Lilly describes retatrutide as investigational, with an application for FDA approval planned for early 2027.

Is there a best supplement for GLP-1 hair loss, or will a multivitamin help?

The sources reviewed for this article do not show that a supplement on its own prevents or resolves GLP-1 related shedding. Nutrition guidance for people taking GLP-1 medicines centers on adequate protein and avoiding micronutrient shortfalls, and a blood test can show whether a deficiency exists. Before starting a GLP-1 medicine, it is reasonable to tell the prescriber about any history of thinning and to ask about nutrition, although no step has been shown to prevent shedding.

Sources

All pages accessed October 12, 2026.

• Novo Nordisk. Wegovy (semaglutide) prescribing information. Revised June 2026. Sections 6.1 (Table 3; Hair Loss) and 12.1–12.2.

• Eli Lilly and Company. Zepbound (tirzepatide) prescribing information. Revised August 2026. Sections 6.1 (Table 1; Hair Loss) and 12.1–12.2.

• Tang H, Zhang B, Lu Y, et al. Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation. BMJ. 2026;394:e100077. doi:10.1136/bmj-2026-100077.

• Hughes EC, Syed HA, Saleh D. Telogen Effluvium. StatPearls. Updated May 1, 2024. PMID 28613598.

• Gupta AK, Teasell EM, Economopoulos V, Mirmirani P. GLP-1 therapies and hair loss: a systematic review of current evidence and implications for counseling. Science Progress. 2026;109(2). doi:10.1177/00368504261444578.

• Ching LM, Guirguis CA, Tung JK. Associations between GLP-1 receptor agonists and alopecia: a multi-centre retrospective analysis and public interest trends. JEADV Clinical Practice. 2025. doi:10.1002/jvc2.70208.

• Zhang W, Fan M, Wang C, et al. Hair loss after metabolic and bariatric surgery: a systematic review and meta-analysis. Obesity Surgery. 2021;31(6):2649–2659.

• Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity. 2025;33(8):1475–1503. doi:10.1002/oby.24336.

• Sievenpiper JL, et al. Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1-based therapies: an expert consensus statement using a modified Delphi approach. Obesity Pillars. 2026;17:100228. doi:10.1016/j.obpill.2025.100228.

• NIH Office of Dietary Supplements. Biotin: Fact Sheet for Health Professionals. Updated January 10, 2022. Sections on recommended intakes, deficiency and interactions with laboratory tests (reports the FDA troponin warning).

• MedlinePlus. Ferritin Blood Test. Last updated March 18, 2025.

• Patel P, Nessel TA, Kumar D D. Minoxidil. StatPearls. Updated February 24, 2023. PMID 29494000. Sections on indications and adverse effects.

• Eli Lilly and Company. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials. News release, July 23, 2026.

This article is for education only and is not medical advice. Talk with your healthcare provider about your own hair and scalp health.